- Home
- NUVL vs MTH Comparison
NUVL vs MTH Comparison
Compare NUVL & MTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- MTH
- Stock Information
- Founded
- NUVL 2017
- MTH 1985
- Country
- NUVL United States
- MTH United States
- Employees
- NUVL N/A
- MTH N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- MTH Homebuilding
- Sector
- NUVL Health Care
- MTH Consumer Discretionary
- Exchange
- NUVL Nasdaq
- MTH Nasdaq
- Market Cap
- NUVL 5.6B
- MTH 4.9B
- IPO Year
- NUVL 2021
- MTH 1988
- Fundamental
- Price
- NUVL $74.61
- MTH $63.58
- Analyst Decision
- NUVL Strong Buy
- MTH Buy
- Analyst Count
- NUVL 8
- MTH 10
- Target Price
- NUVL $115.50
- MTH $74.42
- AVG Volume (30 Days)
- NUVL 548.5K
- MTH 791.4K
- Earning Date
- NUVL 05-08-2025
- MTH 07-23-2025
- Dividend Yield
- NUVL N/A
- MTH 2.70%
- EPS Growth
- NUVL N/A
- MTH N/A
- EPS
- NUVL N/A
- MTH 9.89
- Revenue
- NUVL N/A
- MTH $6,284,888,000.00
- Revenue This Year
- NUVL N/A
- MTH $3.99
- Revenue Next Year
- NUVL N/A
- MTH $7.59
- P/E Ratio
- NUVL N/A
- MTH $6.43
- Revenue Growth
- NUVL N/A
- MTH N/A
- 52 Week Low
- NUVL $55.54
- MTH $59.27
- 52 Week High
- NUVL $113.51
- MTH $106.99
- Technical
- Relative Strength Index (RSI)
- NUVL 54.31
- MTH 40.76
- Support Level
- NUVL $70.25
- MTH $62.76
- Resistance Level
- NUVL $75.97
- MTH $65.95
- Average True Range (ATR)
- NUVL 3.09
- MTH 2.01
- MACD
- NUVL 0.13
- MTH -0.41
- Stochastic Oscillator
- NUVL 79.92
- MTH 7.64
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About MTH Meritage Homes Corporation
Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising ten states: Arizona, California, Colorado, Texas, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Utah. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the homebuilding segment.